Hemoporfin

Drug Profile

Hemoporfin

Alternative Names: FMD; FuMeiDa; Hematoporphyrin monomethyl ether; HMME -Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Latest Information Update: 14 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Hematoporphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Nevus

Most Recent Events

  • 05 Dec 2016 Launched for Nevus in China (IV)
  • 31 Oct 2016 Registered for Nevus in China (IV)
  • 01 Sep 2008 Phase-III clinical trials in Nevus in China (IV) (ChiCTR-TRC-08000213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top